Skip to main content

Day: February 14, 2022

Successful Consumer EV Market Study Reveals Mullen FIVE Scores High Against Tesla Model Y and Ford Mach-E

Results from a comprehensive 6-month EV market exploration study and conceptual benchmark test indicate that the Mullen FIVE is conceptually highly competitive with the Tesla Model Y and Ford Mach-E. Results will support Mullen’s U.S. Department of Energy’s ATVM Loan Application for $450M.Mullen FIVE Scores Well Against Tesla Model Y and Ford Mach-E in Consumer EV Study The Mullen FIVE performs well in a recently completed consumer benchmark study. Results to be utilized in Mullens’ Department of Energy’s ATVM loan application.BREA, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces results from a detailed EV market study and conceptual benchmark comparison of the Mullen FIVE...

Continue reading

Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and financesStudy suggests PFIC caregivers’ quality of life may be comparable to that of cystic fibrosis caregiversBOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease. A multinational, retrospective, cross-sectional study, PICTURE evaluated and quantified the impact that progressive familial intrahepatic cholestasis (PFIC) has on caregivers and found a significant caregiver-reported burden on health-related quality of life (HRQoL), impairment of daily activities, reduced sleep, impact on work productivity, career building challenges...

Continue reading

BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104

ANAHEIM, CA, Feb. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that it has completed its clinical trial agreement with Orange County Research Center (OCRC), located in Tustin, CA, for its first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary. The principal investigator for the trial will be Dr. Joel M. Neutel M.D.  Dr. Neutel is the Director of Research at the Orange County Research Center, where he has served as study principal investigator on several hundred multinational...

Continue reading

Skyharbour’s Partner Company Azincourt Energy Provides Update on Drilling Progress At The East Preston Uranium Project

Vancouver, BC, Feb. 14, 2022 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt), is pleased to provide an update on the 2022 exploration program at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, Canada. Project Location – Western Athabasca Basin, Saskatchewan, Canada:https://www.skyharbourltd.com/_resources/maps/Sky_EastPreston_20211209.jpg Drilling at the East Preston Project commenced on January 24th, and as of Friday, February 11th, 1,334 meters have been completed in 6 drill holes. After some initial startup delays due to the extreme cold weather, two drill rigs are now operational on the project. Four drill holes are complete and two are in progress on the G-Zone. One drill rig is being...

Continue reading

Apollo Funds to Acquire Additional Common Shares of ABC Technologies Holdings Inc.

NEW YORK, Feb. 14, 2022 (GLOBE NEWSWIRE) — AP IX Alpha Holdings (Lux) S.a r.l. (the “Purchaser”), an affiliate of certain funds managed by affiliates of Apollo Global Management, Inc. (the “Apollo Funds”), announced today that, on February 11, 2022, it entered into purchase agreements (the “Agreements”) to purchase up to 10,000,000 common shares (the “Common Shares”) of ABC Technologies Holdings Inc. (“ABC”) from affiliates of Coliseum Capital Management, LLC (the “Seller”). Under the terms of the Agreements, the Purchaser will acquire (i) 5,000,000 Common Shares (the “Initial Transaction Shares”) and (ii) if the Seller participates in ABC’s rights offering (as further described in the rights offering circular of ABC dated January 12, 2022, the “Rights Offering”), the 5,000,000 Common Shares (the “Rights Shares”) that may be issued...

Continue reading

Highland Copper Announces Appointment of Chief Financial Officer

LONGUEUIL, Quebec, Feb. 14, 2022 (GLOBE NEWSWIRE) — Highland Copper Company Inc. (TSXV: HI, OTCQB: HDRSF) (the “Company”) reports changes to its executive team. Effective immediately, Barry O’Shea will be assuming the position of Chief Financial Officer (“CFO”) of the Company and Alain Krushnisky will be stepping down as CFO to devote more time in his role as CFO of other reporting issuers. Barry O’Shea has over 20 years of finance experience across diverse industries and countries. Mr. O’Shea was CFO of Fiore Gold Ltd. from May 2018 until its recent acquisition by Calibre Mining Corp. Prior to that, he spent eight years with New Gold Inc., initially as Vice President of Finance where he oversaw financial reporting, financial planning, internal audit, and tax and then as Vice President, Business Development, responsible for...

Continue reading

Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO). TrinScreen™ HIV Trinity Biotech’s Uni-Gold™ HIV product has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years. Trinity Biotech has developed this new product, TrinScreen™ HIV, specifically for the screening market, a market that is significantly larger than the confirmatory market, with an estimated market size of over USD150m. TrinScreen™ HIV is a rapid test providing results in less than 12 minutes from a finger stick drop of blood and the test has demonstrated excellent performance in both an independent evaluation sponsored by the WHO and in a multi-centre clinical...

Continue reading

Allegiant to Commence 12,000+ Metres of Drilling at Eastside, Including Deep Drilling of High-Grade Zone

Completes Over 6 Km of Roadbuilding RENO, Nevada, Feb. 14, 2022 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is pleased to announce the completion of additional road building at Eastside and the commencement of drilling to occur in March 2022. Allegiant has recently built over 6 kilometres of additional roads over the past few months allowing direct access to the High-Grade Zone (“HGZ”) recently discovered in our last drilling program. The roads will also provide better access to the upcoming drill program at both the East Pediment and the Western Anomaly. Allegiant plans to drill approximately 35 reverse circulation (“RC”) holes and 7 diamond core (“Core”) holes at Eastside in the upcoming drill program set to commence in March 2022 (see map below). Approximately 25 RC holes...

Continue reading

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update

Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumabCommercial launch planning underwayFinanced through the anticipated approval of the ONS-5010 BLAISELIN, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal first quarter ended December 31, 2021. Recent Corporate HighlightsExpanded commercial team with appointment of SVP, Commercial Operations; Closed a $57.5 million gross proceeds equity offering, including full exercise of underwriter’s option to purchase additional...

Continue reading

Water Ways’ Uzbekistan Project Backlog Increases to CAD$9,400,000 After Signing Third Project in Uzbekistan Totaling CAD$2,700,000

Figure 1 ProjectNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“WWT” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producers is pleased to announce the signing, effective February 9, 2022, of a third cotton smart drip irrigation project in Uzbekistan increasing project backlog to be executed in 2022 to over CAD$9,400,000 (compared to $CAD6,700,000 previously disclosed in our press release dated January 31, 2022). The value of the third project in the Bukhara province of Uzbekistan is CAD$2,700,000 and is planned to be completed by the third quarter of 2022. The agreement includes CAD$100,000...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.